 Molishree Joshi
Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carnitine O-Palmitoyltransferase | 2 | 2020 | 46 | 1.260 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2024 | 801 | 0.750 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 51 | 0.610 |
Why?
| | Androgen Antagonists | 1 | 2019 | 82 | 0.600 |
Why?
| | Androgens | 1 | 2019 | 187 | 0.560 |
Why?
| | Cell Proliferation | 6 | 2022 | 2475 | 0.560 |
Why?
| | Head and Neck Neoplasms | 4 | 2024 | 606 | 0.550 |
Why?
| | Lipid Metabolism | 1 | 2020 | 518 | 0.500 |
Why?
| | Cisplatin | 2 | 2024 | 320 | 0.390 |
Why?
| | Cerebellar Neoplasms | 2 | 2022 | 152 | 0.320 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2024 | 252 | 0.320 |
Why?
| | Medulloblastoma | 2 | 2022 | 193 | 0.310 |
Why?
| | Gene Dosage | 1 | 2008 | 140 | 0.280 |
Why?
| | Transgenes | 1 | 2008 | 180 | 0.280 |
Why?
| | Green Fluorescent Proteins | 1 | 2008 | 390 | 0.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2024 | 1396 | 0.250 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1062 | 0.240 |
Why?
| | Cell Line, Tumor | 6 | 2024 | 3412 | 0.230 |
Why?
| | Down Syndrome | 2 | 2022 | 496 | 0.220 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2129 | 0.220 |
Why?
| | Neoplasms | 4 | 2024 | 2671 | 0.220 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2024 | 38 | 0.220 |
Why?
| | Endothelial Cells | 1 | 2008 | 785 | 0.200 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 45 | 0.190 |
Why?
| | Receptor, EphB4 | 1 | 2022 | 34 | 0.190 |
Why?
| | Ephrin-B2 | 1 | 2022 | 47 | 0.190 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 528 | 0.190 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 217 | 0.180 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 102 | 0.170 |
Why?
| | Group II Phospholipases A2 | 1 | 2020 | 9 | 0.170 |
Why?
| | Receptors, Androgen | 1 | 2021 | 150 | 0.160 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 289 | 0.160 |
Why?
| | Phenylthiohydantoin | 1 | 2019 | 42 | 0.160 |
Why?
| | Receptors, Interferon | 1 | 2019 | 52 | 0.160 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2019 | 44 | 0.160 |
Why?
| | DNA Repair | 1 | 2021 | 231 | 0.150 |
Why?
| | Histone Acetyltransferases | 1 | 2019 | 60 | 0.150 |
Why?
| | Trisomy | 1 | 2019 | 80 | 0.150 |
Why?
| | Acetylation | 1 | 2019 | 248 | 0.150 |
Why?
| | Kynurenine | 1 | 2019 | 114 | 0.150 |
Why?
| | Nitriles | 1 | 2019 | 172 | 0.150 |
Why?
| | Benzamides | 1 | 2019 | 216 | 0.150 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2024 | 872 | 0.140 |
Why?
| | Mice | 9 | 2024 | 17787 | 0.140 |
Why?
| | Down-Regulation | 1 | 2020 | 657 | 0.140 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 411 | 0.130 |
Why?
| | Protein Processing, Post-Translational | 1 | 2019 | 465 | 0.130 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 840 | 0.130 |
Why?
| | Esophageal Neoplasms | 1 | 2020 | 321 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 327 | 0.120 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1060 | 0.120 |
Why?
| | Animals | 11 | 2024 | 36940 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2023 | 938 | 0.120 |
Why?
| | Aminopeptidases | 2 | 2024 | 18 | 0.110 |
Why?
| | Transcription Factors | 2 | 2023 | 1719 | 0.110 |
Why?
| | Cell Cycle Proteins | 3 | 2023 | 617 | 0.110 |
Why?
| | Histones | 1 | 2019 | 636 | 0.110 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1276 | 0.110 |
Why?
| | Humans | 17 | 2024 | 137585 | 0.110 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 955 | 0.100 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2018 | 683 | 0.100 |
Why?
| | Adenocarcinoma | 1 | 2020 | 940 | 0.100 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 249 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 2607 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 2 | 2023 | 648 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 674 | 0.080 |
Why?
| | Taq Polymerase | 1 | 2008 | 10 | 0.080 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2008 | 15 | 0.070 |
Why?
| | Apoptosis | 3 | 2023 | 2553 | 0.070 |
Why?
| | Immunotherapy | 2 | 2023 | 641 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 164 | 0.070 |
Why?
| | Adoptive Transfer | 1 | 2008 | 219 | 0.070 |
Why?
| | Plasmids | 1 | 2008 | 363 | 0.070 |
Why?
| | Microscopy, Confocal | 1 | 2008 | 325 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 900 | 0.070 |
Why?
| | Signal Transduction | 1 | 2019 | 5079 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2526 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 5757 | 0.050 |
Why?
| | Organoids | 1 | 2024 | 112 | 0.050 |
Why?
| | Mice, Transgenic | 1 | 2008 | 2167 | 0.050 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2023 | 81 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2023 | 65 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 44 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2008 | 786 | 0.050 |
Why?
| | Centrosome | 1 | 2022 | 71 | 0.050 |
Why?
| | Gene Silencing | 1 | 2023 | 195 | 0.050 |
Why?
| | Mice, Inbred NOD | 1 | 2023 | 601 | 0.050 |
Why?
| | Centrioles | 1 | 2022 | 44 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2023 | 455 | 0.050 |
Why?
| | Lymph Node Excision | 1 | 2022 | 171 | 0.050 |
Why?
| | Cytoskeletal Proteins | 1 | 2022 | 158 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2023 | 378 | 0.040 |
Why?
| | Cilia | 1 | 2022 | 178 | 0.040 |
Why?
| | Quinazolines | 1 | 2022 | 251 | 0.040 |
Why?
| | Tissue Banks | 1 | 2020 | 16 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3284 | 0.040 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 22 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2021 | 139 | 0.040 |
Why?
| | Quinolinic Acid | 1 | 2019 | 8 | 0.040 |
Why?
| | Biosynthetic Pathways | 1 | 2019 | 24 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2022 | 1236 | 0.040 |
Why?
| | Piperazines | 1 | 2022 | 350 | 0.040 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 56 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2022 | 319 | 0.040 |
Why?
| | Microtubules | 1 | 2022 | 279 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 698 | 0.040 |
Why?
| | Pyrazoles | 1 | 2022 | 423 | 0.040 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2018 | 36 | 0.040 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2018 | 86 | 0.040 |
Why?
| | Barrett Esophagus | 1 | 2020 | 149 | 0.030 |
Why?
| | Receptor, ErbB-2 | 1 | 2020 | 341 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2024 | 1091 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 614 | 0.030 |
Why?
| | Male | 2 | 2021 | 67762 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2023 | 1991 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1502 | 0.030 |
Why?
| | Metabolomics | 1 | 2019 | 678 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2847 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1774 | 0.030 |
Why?
| | Prognosis | 1 | 2021 | 4030 | 0.020 |
Why?
| | Cytokines | 1 | 2019 | 2085 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 7604 | 0.020 |
Why?
| | Child | 1 | 2022 | 21935 | 0.010 |
Why?
|
|
Joshi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|